Castle Biosciences, Inc.
CSTL
$25.62
-$0.29-1.10%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 87.01M | 83.04M | 86.19M | 87.99M | 86.31M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 87.01M | 83.04M | 86.19M | 87.99M | 86.31M |
| Cost of Revenue | 18.32M | 18.70M | 17.63M | 16.38M | 16.18M |
| Gross Profit | 68.70M | 64.34M | 68.56M | 71.61M | 70.13M |
| SG&A Expenses | 56.73M | 55.91M | 58.07M | 58.62M | 49.97M |
| Depreciation & Amortization | 2.28M | 2.28M | 1.96M | 28.33M | 4.34M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 90.84M | 89.85M | 90.44M | 115.92M | 82.26M |
| Operating Income | -3.83M | -6.80M | -4.25M | -27.93M | 4.05M |
| Income Before Tax | -2.71M | -386.00K | -143.00K | -26.27M | 7.89M |
| Income Tax Expenses | -382.00K | 115.00K | -4.67M | -423.00K | -1.71M |
| Earnings from Continuing Operations | -2.33M | -501.00K | 4.52M | -25.85M | 9.59M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.33M | -501.00K | 4.52M | -25.85M | 9.59M |
| EBIT | -3.83M | -6.80M | -4.25M | -27.93M | 4.05M |
| EBITDA | -50.00K | -1.17M | -837.00K | 1.84M | 9.82M |
| EPS Basic | -0.08 | -0.02 | 0.16 | -0.90 | 0.34 |
| Normalized Basic EPS | -0.02 | -0.08 | -0.03 | -0.54 | 0.16 |
| EPS Diluted | -0.08 | -0.02 | 0.15 | -0.90 | 0.31 |
| Normalized Diluted EPS | -0.02 | -0.08 | -0.03 | -0.54 | 0.15 |
| Average Basic Shares Outstanding | 29.33M | 29.07M | 28.91M | 28.61M | 28.13M |
| Average Diluted Shares Outstanding | 29.33M | 29.07M | 29.55M | 28.61M | 30.20M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |